{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "CB1 receptor",
      "animal models",
      "anxiety",
      "anxiolytics",
      "cannabinoids",
      "elevated plus maze"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35984927",
  "DateCompleted": {
    "Year": "2023",
    "Month": "02",
    "Day": "09"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "03",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "08",
        "Day": "17"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1089/can.2022.0078"
    ],
    "Journal": {
      "ISSN": "2378-8763",
      "JournalIssue": {
        "Volume": "8",
        "Issue": "1",
        "PubDate": {
          "Year": "2023",
          "Month": "Feb"
        }
      },
      "Title": "Cannabis and cannabinoid research",
      "ISOAbbreviation": "Cannabis Cannabinoid Res"
    },
    "ArticleTitle": "Effects of \u0394<sup>9</sup>-THC and Type-1 Cannabinoid Receptor Agonists in the Elevated Plus Maze Test of Anxiety: A Systematic Review and Meta-Analysis.",
    "Pagination": {
      "StartPage": "24",
      "EndPage": "33",
      "MedlinePgn": "24-33"
    },
    "Abstract": {
      "AbstractText": [
        "\u0394<sup>9</sup>-THC (the main active compound from <i>Cannabis sativa</i>) and related cannabinoids have been used as drugs of abuse and as medications. They induce a complex set of emotional responses in humans and experimental animals, consisting of either anxiolysis or heightened anxiety. These discrepant effects pose a major challenge for data reproducibility and for developing new cannabinoid-based medicines. In this study, we review and analyze previous data on cannabinoids and anxiety-like behavior in experimental animals. Systematic review and meta-analysis on the effects of type-1 cannabinoid receptor agonists (full or partial, selective or not) in rodents exposed to the elevated plus maze, a widely used test of anxiety-like behavior. Cannabinoids tend to reduce anxiety-like behavior if administered at low doses. THC effects are moderated by the dose factor, with anxiolytic- and anxiogenic-like effects occurring at low-dose (0.075-1\u2009mg/kg) and high-dose (1-10\u2009mg/kg) ranges, respectively. However, some studies report no effect at all regardless of the dose tested. Finally, motor impairment represents a potential confounding factor when high doses are administered. The present analysis may contribute to elucidate the experimental factors underlying cannabinoid effects on anxiety-like behavior and facilitate data reproducibility in future studies."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Graduate School in Neuroscience; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacology; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          }
        ],
        "LastName": "Iglesias",
        "ForeName": "Lia P",
        "Initials": "LP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacology; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          }
        ],
        "LastName": "Bedeschi",
        "ForeName": "Lucas",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Graduate School in Neuroscience; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacology; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          },
          {
            "Identifier": [],
            "Affiliation": "Graduate School in Physiology and Pharmacology; Institute of Biological Sciences, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          }
        ],
        "LastName": "Aguiar",
        "ForeName": "Daniele C",
        "Initials": "DC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Graduate School in Neuroscience; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          },
          {
            "Identifier": [],
            "Affiliation": "Graduate School in Physiology and Pharmacology; Institute of Biological Sciences, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          }
        ],
        "LastName": "Asth",
        "ForeName": "Laila",
        "Initials": "L"
      },
      {
        "Identifier": [
          "0000-0002-0824-7302"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Graduate School in Neuroscience; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacology; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          },
          {
            "Identifier": [],
            "Affiliation": "Graduate School in Physiology and Pharmacology; Institute of Biological Sciences, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil."
          }
        ],
        "LastName": "Moreira",
        "ForeName": "Fabr\u00edcio A",
        "Initials": "FA"
      }
    ],
    "PublicationTypeList": [
      "Meta-Analysis",
      "Systematic Review",
      "Journal Article",
      "Review",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cannabis Cannabinoid Res",
    "NlmUniqueID": "101684827",
    "ISSNLinking": "2378-8763"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cannabinoid Receptor Agonists"
    },
    {
      "RegistryNumber": "7J8897W37S",
      "NameOfSubstance": "Dronabinol"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cannabinoids"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Cannabinoid Receptor Agonists"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Dronabinol"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Elevated Plus Maze Test"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Reproducibility of Results"
    },
    {
      "QualifierName": [
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Cannabinoids"
    }
  ]
}